TPX 100

Drug Profile

TPX 100

Alternative Names: TPX100

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OrthoTrophix
  • Class Antirheumatics; Glycoproteins
  • Mechanism of Action Collagen modulators; Extracellular matrix protein modulators; Integrin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 01 Jul 2017 OrthoTrophix initiates enrolment in an observational study for Osteoarthritis in US (NCT03125499)
  • 26 Apr 2017 OrthoTrophix plans an observational trial for Osteoarthritis in US (NCT03125499)
  • 22 Jul 2016 OrthoTrophix plans a phase II trial for Osteoarthritis in USA (NCT02837900)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top